Correction to: BMC Nephrol (2019) 20:90
https://doi.org/10.1186/s12882-019-1209-1
Anzeige
Following publication of the original article [1], the authors reported errors in the presentation of Tables 2, 4 and 5. Additionally, the authors reported an error in the last paragraph of the ‘Safety assessment’ section and an error in the first paragraph of the ‘Discussion’ section. In this Correction the incorrect and correct version of Tables 2, 4 and 5 and the incorrect and correct version of the sentences in the ‘Safety assessment’ and ‘Discussion’ section are shown.
Originally Table 2 was published as:
Table 2
Mean Hb levels (g/dL) and mean change in hemoglobin from Baseline to EOC – Dialysis, ITT Population (N = 126)
Statistics | ITT Population (N = 126) | PP Population (N = 93) | ||
|---|---|---|---|---|
Darbepoetin alfa (n = 63) | Erythropoietin alfa (n = 63) | Darbepoetin alfa (n = 47) | Erythropoietin alfa (n = 46) | |
Baseline | ||||
n | 56 | 53 | 47 | 46 |
Mean (SD) | 8.39 (0.90) | 8.80 (0.89) | 8.39 (0.85) | 8.72 (0.91) |
End of first evaluation visit | ||||
n | 55 | 51 | 47 | 46 |
Mean (SD) | 10.20 (1.74) | 10.61 (1.55) | 10.33 (1.42) | 10.90 (0.95) |
Within group comparison | ||||
p-value# | <.0001 | <.0001 | <.0001 | <.0001 |
Mean change | 1.84 | 1.85 | 1.94 | 2.18 |
95% CI | [1.36–2.32] | [1.37–2.33] | [1.48–2.40] | [1.84–2.53] |
Between group comparison | ||||
Mean change | −0.01 | −0.24 | ||
95% CI | [−0.68–0.66] | [− 0.81–0.32] | ||
p-value** | 0.9703 | 0.3985 | ||
The correct version of Table 2, with the corrected sections indicated in bold:
Table 2
Mean Hb levels (g/dL) and mean change in hemoglobin from Baseline to EOC – Dialysis, ITT Population (N = 126)
Statistics | ITT Population (N = 126) | PP Population (N = 93) | ||
|---|---|---|---|---|
Darbepoetin alfa (n = 63) | Erythropoietin alfa (n = 63) | Darbepoetin alfa (n = 47) | Erythropoietin alfa (n = 46) | |
Baseline | ||||
n | 56 | 53 | 47 | 46 |
Mean (SD) | 8.39 (0.90) | 8.80 (0.89) | 8.39 (0.85) | 8.72 (0.91) |
End of first evaluation visit | ||||
n | 55 | 51 | 47 | 46 |
Mean (SD) | 10.20 (1.74) | 10.61 (1.55) | 10.33 (1.42) | 10.90 (0.95) |
Within group comparison | ||||
p-value# | <.0001 | <.0001 | <.0001 | <.0001 |
Mean change | 1.84 | 1.85 | 1.94 | 2.18 |
95% CI | [1.36–2.32] | [1.37–2.33] | [1.48–2.40] | [1.84–2.53] |
Between group comparison | ||||
Mean change | −0.01 | −0.24 | ||
95% CI | [−0.68–0.66] | [− 0.81–0.32] | ||
p-value** | 0.9703 | 0.3985 | ||
Originally Table 4 was published as:
Table 4
Mean change in hemoglobin levels (g/dL) from baseline to week-4
Statistics | ITT Population (N = 126) | PP Population (N = 93) | ||
|---|---|---|---|---|
Darbepoetin alfa (n = 63) | Erythropoietin alfa (n = 63) | Darbepoetin alfa (n = 47) | Erythropoietin alfa (n = 46) | |
Baseline | ||||
n | 56 | 53 | 47 | 46 |
Mean (SD) | 8.39 (0.90) | 8.80 (0.89) | 8.39 (0.85) | 8.72 (0.91) |
Week-4 | ||||
n | 55 | 50 | 47 | 45 |
Mean (SD) | 8.66 (1.24) | 9.50 (1.81) | 8.68 (1.13) | 9.62 (1.71) |
Within group comparison | ||||
p-value* | 0.0566 | 0.0019 | 0.0473 | 0.0002 |
Mean change | 0.30 | 0.74 | 0.29 | 0.91 |
95% CI | [− 0.01–0.61] | [0.29–1.19] | [0.00–0.57] | [0.45–1.36] |
Between group comparison | ||||
Mean change | −0.44 | −0.62 | ||
95% CI | [−0.97–0.09] | [−1.14–0.10] | ||
p-value** | 0.1057 | 0.0209 | ||
Anzeige
The correct version of Table 4, with the corrected sections indicated in bold:
Table 4
Mean change in hemoglobin levels (g/dL) from baseline to week-4
Statistics | ITT Population (N = 126) | PP Population (N = 93) | ||
|---|---|---|---|---|
Darbepoetin alfa (n = 63) | Erythropoietin alfa (n = 63) | Darbepoetin alfa (n = 47) | Erythropoietin alfa (n = 46) | |
Baseline | ||||
n | 56 | 53 | 47 | 46 |
Mean (SD) | 8.39 (0.90) | 8.80 (0.89) | 8.39 (0.85) | 8.72 (0.91) |
Week-4 | ||||
n | 55 | 50 | 47 | 45 |
Mean (SD) | 8.66 (1.24) | 9.50 (1.81) | 8.68 (1.13) | 9.62 (1.71) |
Within group comparison | ||||
p-value* | 0.0566 | 0.0019 | 0.0473 | 0.0002 |
Mean change | 0.30 | 0.74 | 0.29 | 0.91 |
95% CI | [− 0.01–0.61] | [0.29–1.19] | [0.00–0.57] | [0.45–1.36] |
Between group comparison | ||||
Mean change | −0.44 | − 0.62 | ||
95% CI | [−0.97–0.09] | [−1.14–0.10] | ||
p-value** | 0.1057 | 0.0209 | ||
Originally Table 5 was published as:
Table 5
Time to initially attained target Hb level (10–12 g/dL) and proportion of patients attained target Hb level (10–12 g/dL) at EOC and EOM
Parameter | ITT Population (N = 126) | PP Population (N = 93) | ||
|---|---|---|---|---|
Darbepoetin alfa (n = 63) | Erythropoietin alfa (n = 63) | Darbepoetin alfa (n = 47) | Erythropoietin alfa (n = 46) | |
Number of weeks to initially attain target Hb | ||||
Median (95%CI) | 9.00 (7.00–11.00) | 7.00 (4.00–9.00) | 9.00 (7.00–10.00) | 7.00 (4.00–8.00) |
No. of Patients initially attained target Hb level | ||||
N (%) | 44 (78.57) | 43 (82.69) | 40 (85.10) | 41 (89.13) |
Hazard Ratio (95%CI) | 0.807 (0.53–1.23) | 0.778 (0.50–1.21) | ||
P Value | 0.3212 | 0.2608 | ||
No. of patients attained target Hb level at EOC | ||||
N (%) | 33 (52.38) | 31 (49.2) | 32 (68.08) | 32 (69.56) |
Odd ratios (95%CI) | 0.9559 (0.46–1.99) | 0.9410 (0.39–2.30) | ||
P value | 0.9038 | 0.8938 | ||
No. of patients maintained target Hb level at EOM | ||||
(%) | 24 (38.10) | 36 (57.14) | 15 (34.09) | 23 (57.50) |
Odd ratios (95%CI) | 0.5748 (0.26–1.25) | 0.4567 (0.17–1.22) | ||
P Value | 0.1621 | 0.1180 | ||
The correct version of Table 5, with the corrected sections indicated in bold:
Table 5
Time to initially attained target Hb level (10–12 g/dL) and proportion of patients attained target Hb level (10–12 g/dL) at EOC and EOM
Parameter | ITT Population (N = 126) | PP Population (N = 93) | ||
|---|---|---|---|---|
Darbepoetin alfa (n = 63) | Erythropoietin alfa (n = 63) | Darbepoetin alfa (n = 47) | Erythropoietin alfa (n = 46) | |
Number of weeks to initially attain target Hb | ||||
Median (95%CI) | 9.00 (7.00–11.00) | 7.00 (4.00–9.00) | 9.00 (7.00–10.00) | 7.00 (4.00–8.00) |
No. of Patients initially attained target Hb level | ||||
N (%) | 44 (78.57) | 43 (82.69) | 40 (85.10) | 41 (89.13) |
Hazard Ratio (95%CI) | 0.807 (0.53–1.23) | 0.778 (0.50–1.21) | ||
p-value | 0.3212 | 0.2608 | ||
No. of patients attained target Hb level at EOC | ||||
N (%) | 33 (52.38) | 31 (49.2) | 32 (68.08) | 32 (69.56) |
Odd ratios (95%CI) | 0.9559 (0.46–1.99) | 0.9410 (0.39–2.30) | ||
p-value | 0.9038 | 0.8938 | ||
No. of patients maintained target Hb level at EOM | ||||
(%) | 24 (38.10) | 36 (57.14) | 15 (34.09) | 23 (57.50) |
Odd ratios (95%CI) | 0.5748 (0.26–1.25) | 0.4567 (0.17–1.22) | ||
p-value | 0.1621 | 0.1180 | ||
Originally the last paragraph of the ‘Safety assessment’ section was published as:
- Altogether, DA-α had a similar safety profile to that of EPO and no antibody formation was identified.
The correct presentation of the last paragraph of the ‘Safety assessment’ section, with the corrected words indicated in bold:
- Altogether, DA-α had a similar safety profile to that of EPO and no anti-drug antibody formation was identified.
Originally two sentences in the first paragraph of the ‘Discussion’ section were published as:
- Evaluating the iron availability for erythropoeisis is crucial in treating anaemia patients with CKD.Iron deficiency can interfere with the response to EPO and DA-α and affecting the efficacy
The correct presentation of two sentences in the first paragraph of the ‘Discussion’ section, with the corrected words indicated in bold:
- Evaluating the iron availability for erythropoeisis is crucial in treating anaemia patients with CKD. Iron deficiency can interfere with the response to EPO and DA-α and affecting the efficacy
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.